GLUE
Monte Rosa Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$10.76Close
$705.3MMarket cap
$9.74 – $25.3152-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 7 · weaker than 93% of stocks over 12 months
- Far from its high 57% below its 52-week high
- Distribution down-day volume 1.5× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
57%
1wk
down 0.7%
price change
1mo
down 9.8%
price change
12-month return
down 17%
market up 11% ·
its own down 25%
F-score
—
— Not assessed
Altman Z
1.23
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.0×
price / book
Earnings yield
down 9.4%
EBIT / enterprise value
Cheaper than
25%
of the market · expensive
Revenue growth
up 64%
year on year
EPS growth
—
latest quarter
Sales growth
down 61%
latest quarter · +34 pts
ROE
down 17%
return on equity
Free cash margin
down 22%
-$27.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.7%
$0.61 a day · 2×ATR $9.54
RS
7 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.65
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 6.6% over the year, from 62m to 66m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Jul 31, 2026-27% in one session4.7× volumeno filing matched-35% since
Financials
- Net -31%
- Free cash -22%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $75.6M | $123.7M |
| Operating income | -$28.0M | -$72.9M | -$112.4M | -$143.3M | -$81.1M | -$54.2M |
| Net income | -$35.9M | -$74.0M | -$108.5M | -$135.4M | -$72.7M | -$38.6M |
| Net margin | — | — | — | — | -96% | -31% |
| Earnings per share | — | -$2.96 | -$2.30 | -$2.63 | -$0.98 | -$0.46 |
| Free cash flow | -$26.4M | -$69.1M | -$105.4M | -$62.8M | $38.0M | -$27.5M |
| Free cash margin | — | — | — | — | 50% | -22% |
| Cash | $41.7M | $346.1M | $54.9M | $128.1M | $224.3M | $129.9M |
| Shareholders' equity | -$48.7M | $347.5M | $271.4M | $179.2M | $222.9M | $233.1M |
| Shares outstanding | 1.69m | 46.54m | 49.32m | 50.14m | 61.51m | 65.54m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 17, 2026 | Annual ↗ | Dec 31, 2025 | 76d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 1, 2026 | Regulation FD · Other events ↗ |
| Sep 8, 2026 | Regulation FD · Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 11, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 17, 2026 | Results ↗ |
| Feb 10, 2026 | Director or officer change ↗ |
| Jan 9, 2026 | Material agreement · Other events ↗ |
| Jan 7, 2026 | Other events ↗ |
| Jan 7, 2026 | Regulation FD · Other events ↗ |
| Dec 16, 2025 | Regulation FD · Other events ↗ |
| Nov 6, 2025 | Results · Regulation FD ↗ |